(SLP) Simulations Plus - Ratings and Ratios

Simulations Plus, Inc. (NASDAQ:SLP) is a leader in developing advanced software solutions for drug discovery and development, leveraging cutting-edge artificial intelligence and machine learning technologies. The companys product portfolio includes GastroPlus, which models the absorption and drug interactions in humans and animals, as well as DDDPlus and MembranePlus for simulations. Additionally, it offers a suite of mechanistic models such as DILIsym, NAFLDsym, and OBESITYsym, which are used to simulate various physiological conditions. The company also provides Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME Tox) Predictor software for chemistry-based property predictions, MedChem Designer for molecular design, and MonolixSuite for population pharmacokinetic and pharmacodynamic modeling. Its consulting services span population pharmacokinetic modeling, exposure-response analyses, clinical trial simulations, and regulatory submissions support. The company serves a diverse range of industries, including pharmaceuticals, biotechnology, agrochemicals, cosmetics, and food, as well as academic and regulatory institutions. Founded in 1996 and headquartered in Lancaster, California, Simulations Plus has established itself as a key player in the health care technology sector. Web URL: https://www.simulations-plus.com.

Based on the provided technical and fundamental data, Simulations Plus, Inc. (NASDAQ:SLP) is currently trading at $29.01, below its 20-day simple moving average (SMA) of $32.50 and 200-day SMA of $31.80, but above its 50-day SMA of $28.85. This indicates short-term bearish momentum but potential support near the 50-day SMA. The Average True Range (ATR) of $1.98 suggests moderate volatility. On the fundamental side, the company has a market capitalization of $715.69 million, with a trailing P/E of 97.81 and a forward P/E of 31.95, indicating high valuation relative to current earnings but expectations of improved future profitability. The price-to-book (P/B) ratio of 3.77 and price-to-sales (P/S) ratio of 9.11 reflect a premium valuation. The return on equity (RoE) of 3.91% is relatively low, suggesting modest profitability compared to equity. Overall, the stock appears overvalued based on current earnings but may align with growth expectations.